Clinical Trial Update: A Study of Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT) [Phase 3]

View source ↗

Summary

Phase 3 trial updating ocrelizumab in relapsing-remitting MS patients with suboptimal response to prior DMT has completed and results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis Relapsing-remitting

Drugs mentioned

• Ocrelizumab (ocrelizumab)

Snippet

Sponsor: Genentech, Inc. | Conditions: Multiple Sclerosis, Relapsing-Remitting | Phase 3 | Status: COMPLETED | Results posted: 2020-05-26